Juergen Wolf — ASN Events

Juergen Wolf — ASN Events

, ,

Presentations this author is a contributor to:

Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC) (#200)